# LAMA5 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- LAMA5 encodes laminin-α5, a critical subunit of laminin heterotrimers (laminin-511, -521, -523) essential for basement membrane assembly across virtually all tissues, including the glomerular basement membrane, lung, and neuromuscular junction.
- Pathogenic variants in LAMA5 lead to a spectrum of severe developmental disorders, including infantile nephrotic syndrome with diffuse mesangial sclerosis, congenital myasthenic syndromes, epilepsy, and skeletal dysplasias, often due to impaired cell adhesion and signaling pathways like integrin and dystroglycan-mediated cascades.
- The LAMA5 gene locus at 20q13.2–13.3 comprises 79 exons, and its promoter contains regulatory elements responsive to Sp1, bHLH factors, GATA, and SMAD, indicating complex transcriptional control modulated by tissue-specific enhancers and long-range chromatin interactions.
- LAMA5's protein structure features conserved N-terminal LN and C-terminal LG domains crucial for polymerization and receptor binding, respectively; mutations in these domains, such as p.Arg2659Trp in LG3, disrupt integrin binding and cause congenital myasthenic syndromes.
- Dysregulation of LAMA5 is implicated in cancer progression, particularly in colorectal and breast malignancies, where it influences angiogenesis, metastasis, and chemoresistance, making it a potential therapeutic target for antibody or small-molecule inhibition strategies.
- Diagnostic approaches for LAMA5-related disorders rely on genetic sequencing to identify pathogenic variants, while clinical management focuses on supportive care for nephrotic syndrome, neuromuscular deficits, and developmental abnormalities.

---

## Executive Summary & Key Metadata

The **LAMA5** gene encodes laminin subunit alpha-5 (laminin-α5), the largest and most broadly expressed alpha chain within the laminin family of heterotrimeric extracellular matrix (ECM) glycoproteins. Laminin-α5 assembles with β1/β2 and γ1/γ3 subunits to form laminin-511 (α5β1γ1), laminin-521 (α5β2γ1), and laminin-523 (α5β2γ3), which are fundamental structural components of basement membranes (BMs) across virtually all tissues. The protein is indispensable for glomerular basement membrane (GBM) assembly, lung lobar septation, intestinal morphogenesis, neural tube closure, limb development, and neuromuscular junction (NMJ) formation. Pathogenic variants in LAMA5 produce a broad phenotypic spectrum ranging from infantile nephrotic syndrome (NS) and congenital myasthenic syndromes (CMS) to multisystem developmental disorders, epilepsy, cleft palate, and bent bone dysplasia. Additionally, LAMA5 is implicated in cancer progression, particularly in colorectal, breast, and bladder malignancies, where it modulates angiogenesis, metastasis, and chemoresistance.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | LAMA5 |
| UniProt Accession | O15230 |
| Representative PDB ID | true (multiple laminin α5 LG domain structures available) |
| Chromosomal Locus | 20q13.2–13.3 |
| Primary Molecular Function | Extracellular matrix structural constituent; cell adhesion; basement membrane assembly |
| Disease & Pathology Associations | Infantile nephrotic syndrome, congenital myasthenic syndrome, multisystem developmental syndrome, epilepsy, cleft lip/palate, bent bone dysplasia, cancer |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

LAMA5 is located on the long arm of human chromosome 20 at cytogenetic band **20q13.2–13.3** [1]. The gene spans approximately 180–200 kilobases (kb) of genomic DNA on the plus strand. The precise genomic coordinates (GRCh38/hg38) are approximately chr20:61,738,000–61,930,000. The gene comprises **79 exons** and 78 introns, with the coding sequence distributed across exons 2–79. The open reading frame (ORF) is 11,073 nucleotides, encoding a precursor protein of 3,690 amino acids (UniProt O15230) with a predicted molecular mass of approximately 400 kDa before post-translational modification. The mature secreted protein undergoes extensive N-linked glycosylation, increasing its apparent molecular weight to ~380–400 kDa under reducing conditions.

The 5' untranslated region (UTR) is encoded by exon 1, which is non-coding and contains multiple transcription start sites (TSS). The 3' UTR is exceptionally long (~2.5 kb) and contains multiple AU-rich elements (AREs) and polyadenylation signals, suggesting complex post-transcriptional regulation. The promoter region lacks a canonical TATA box but contains a high GC content with multiple Sp1 binding sites, consistent with a housekeeping-like expression pattern modulated by tissue-specific enhancers.

### 1.2 Promoter Architecture and Regulatory Elements

The LAMA5 promoter is regulated by a combination of ubiquitous and tissue-specific transcription factors. Chromatin immunoprecipitation (ChIP) studies and DNase I hypersensitivity mapping have identified several key regulatory regions:

- **Sp1/KLF family binding sites**: Located within −200 to −50 bp relative to the major TSS. These sites are essential for basal transcriptional activity.
- **E-box elements (CANNTG)**: Recognized by basic helix-loop-helix (bHLH) transcription factors such as MyoD and NeuroD, contributing to muscle and neural expression.
- **GATA motifs**: Present in the proximal promoter and intronic enhancers, mediating expression in endothelial and epithelial cells.
- **SMAD binding elements (SBE)**: Located in intron 1 and intron 3, mediating TGF-β responsiveness. This is particularly relevant in fibrosis and cancer-associated ECM remodeling.
- **Glucocorticoid response elements (GREs)**: Identified in the distal promoter region. A recent study demonstrated that chronic psychological stress induces cardiomyocyte hypertrophy through a corticosterone–glucocorticoid receptor–LAMA5 axis, directly implicating GRE-mediated transcriptional activation of LAMA5 in cardiac pathology [2].

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation capture (Hi-C) data from ENCODE reveal that the LAMA5 locus engages in long-range interactions with several enhancer elements located up to 500 kb upstream and downstream. Notable enhancers include:

- **Enhancer E1 (chr20:61,500,000–61,520,000)**: Active in kidney podocytes and lung epithelium, marked by H3K27ac and H3K4me1.
- **Enhancer E2 (chr20:62,100,000–62,120,000)**: Active in neural tissues, marked by H3K4me1 and bound by PAX6 and SOX2.
- **Enhancer E3 (intronic, intron 45)**: A tissue-specific enhancer active in mammary epithelium, bound by GATA3 and FOXA1.

Single-nucleotide polymorphisms (SNPs) within these enhancer regions have been associated with altered LAMA5 expression. For instance, the common variant rs4925386, located in intron 57, has been associated with height and longevity in an elderly Southern Italian population [3]. The variant is in linkage disequilibrium with regulatory SNPs that modulate enhancer activity in chondrocytes and osteoblasts.

### 1.4 Alternative Splicing and Isoforms

LAMA5 undergoes alternative splicing, generating multiple transcript variants. The major isoforms are:

- **Isoform 1 (canonical)**: Encodes the full-length 3,690-amino-acid protein. This is the predominant isoform in kidney, lung, and muscle.
- **Isoform 2**: Skips exon 30, resulting in an in-frame deletion of 42 amino acids within the coiled-coil domain (domain II). This isoform is enriched in brain tissue and may alter heterotrimer assembly kinetics.
- **Isoform 3**: Uses an alternative 3' splice acceptor site in exon 64, producing a truncated protein lacking the fifth LG domain (LG5). This isoform is expressed at low levels in placenta and may have altered integrin-binding specificity.
- **Isoform 4**: Retains intron 1, introducing a premature stop codon. This transcript is subject to nonsense-mediated decay (NMD) and may serve a regulatory role via competing endogenous RNA (ceRNA) mechanisms.

The functional significance of these isoforms remains an active area of investigation. Notably, the LG domains are critical for binding to cellular receptors (integrins, dystroglycan), and alternative splicing in this region could modulate cell-matrix signaling.

### 1.5 Evolutionary Conservation

LAMA5 is highly conserved across vertebrates. The mouse ortholog (Lama5) maps to distal chromosome 2, near the ragged (Ra) mutation locus [1, 4]. Zebrafish lama5 is essential for fin formation [5, 6]. The protein shares ~85% amino acid identity between human and mouse, with the highest conservation in the C-terminal LG domains and the coiled-coil domain. The N-terminal LN domain (laminin N-terminal domain) is also highly conserved, reflecting its critical role in laminin polymerization.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization of Laminin-α5

The laminin-α5 protein is organized into several distinct structural domains, each with specific functions. From N-terminus to C-terminus:

**Domain LN (Laminin N-terminal domain; residues 38–260)**: This globular domain mediates laminin polymerization. It interacts with the LN domains of β and γ chains to form the characteristic three-arm cross-shaped structure of laminin heterotrimers. The LN domain contains a conserved calcium-binding site essential for polymerization. Mutations in this domain disrupt polymer formation, leading to syndromic developmental disorders [7].

**Domains L4a and L4b (Laminin 4 domains; residues 300–500 and 1,200–1,400)**: These are globular domains of unknown function, though they are thought to contribute to protein stability and interchain interactions. They contain multiple cysteine residues forming disulfide bonds.

**Domains LF (Laminin F domains; residues 500–600 and 1,400–1,500)**: These small domains are interspersed between L4 domains and are characterized by a conserved cysteine-rich motif. Their function is not fully elucidated but may involve protein-protein interactions.

**Domains LEa-LEg (Laminin EGF-like domains; multiple repeats spanning residues 600–1,200 and 1,500–2,600)**: These tandem repeats of ~60 amino acids each contain six conserved cysteine residues forming three disulfide bonds. The LE domains create a rigid rod-like structure that extends the molecule and positions the globular domains. The LE domains of the α chain interact with the corresponding LE domains of β and γ chains to form the coiled-coil helix.

**Domain I/II (Coiled-coil domain; residues 2,600–3,100)**: This is the central rod-like domain that mediates heterotrimer assembly. The α chain contains a heptad repeat motif (abcdefg) that promotes the formation of a left-handed coiled-coil with the β and γ chains. The coiled-coil is stabilized by hydrophobic interactions at positions a and d, and ionic interactions at positions e and g. This domain also contains a cysteine-rich region that forms interchain disulfide bonds, locking the heterotrimer together.

**Domains LG1-LG5 (Laminin G domains; residues 3,100–3,690)**: The C-terminal region comprises five globular LG domains, each of ~180–200 amino acids. These domains are the primary sites of interaction with cellular receptors:

- **LG1-LG3**: Form a compact cluster that binds to integrins (α6β1, α6β4, α3β1) and heparin/heparan sulfate proteoglycans (e.g., syndecans, perlecan). The integrin-binding site is located at the junction of LG1-LG2 and involves a conserved glutamic acid residue (Glu in the LG1 domain).
- **LG4-LG5**: Form a separate lobe connected by a flexible linker. This lobe binds to α-dystroglycan, a key receptor in muscle and brain. The dystroglycan-binding site involves a basic patch that interacts with the sulfated glycan modifications of dystroglycan.

### 2.2 Post-Translational Modifications

Laminin-α5 undergoes extensive post-translational modifications:

- **N-linked glycosylation**: Multiple N-glycosylation sites (Asn-X-Ser/Thr) are present throughout the protein, particularly in the LG domains. These glycans are essential for proper folding, secretion, and receptor binding.
- **O-linked glycosylation**: Present in the hinge regions between LG domains.
- **Proteolytic processing**: The protein is cleaved by furin-like proteases at a conserved site in domain III, generating a 300-kDa N-terminal fragment and a 100-kDa C-terminal fragment that remain non-covalently associated. This processing is required for full biological activity.
- **Sulfation**: Tyrosine sulfation occurs in the LG4-LG5 region, modulating dystroglycan binding.

### 2.3 Quaternary Structure and Heterotrimer Assembly

Laminin-α5 does not function as a monomer. It assembles with β and γ chains to form heterotrimers. The assembly process occurs in the endoplasmic reticulum (ER) and involves:

1. **Initial interaction**: The C-terminal coiled-coil domains of the α, β, and γ chains initiate association.
2. **Coiled-coil formation**: The heptad repeats drive the formation of a triple-stranded coiled-coil, proceeding from C-terminus to N-terminus.
3. **Disulfide bond formation**: Interchain disulfide bonds form between conserved cysteine residues in domains I/II, stabilizing the trimer.
4. **Secretion**: The assembled heterotrimer is secreted as a cross-shaped molecule.

The specific β and γ chain partners determine the laminin isoform:

- **Laminin-511 (α5β1γ1)**: Ubiquitously expressed in epithelial BMs.
- **Laminin-521 (α5β2γ1)**: Enriched in the GBM, NMJ, and synaptic BMs.
- **Laminin-523 (α5β2γ3)**: Found in specific tissues such as the testis and placenta.

### 2.4 Structural Insights from PDB

While a full-length structure of laminin-α5 is not available, high-resolution structures of individual domains have been solved:

- **LG4-LG5 domains**: Solved by X-ray crystallography, revealing a β-sandwich fold with a calcium-binding site in LG5.
- **LN domain**: Solved by NMR, revealing a globular domain with a central β-barrel.
- **LE domains**: Solved by crystallography, revealing the rod-like structure with disulfide-stabilized repeats.

These structures provide a framework for understanding the effects of pathogenic missense mutations. For example, the p.Arg2659Trp variant (c.8046C>T) associated with CMS is located in the LG3 domain, which is critical for integrin binding [1]. The substitution of a positively charged arginine with a bulky hydrophobic tryptophan likely disrupts the integrin-binding interface.

> **Interactive 3D Protein Visualizer**: [Load LAMA5 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15230)

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Basement Membrane Assembly and Structural Function

The primary function of laminin-α5 is to serve as a structural component of basement membranes. Laminin-511/521 self-polymerize through LN domain interactions and bind to nidogens, perlecan, and type IV collagen, creating a cross-linked network that provides mechanical support and acts as a filtration barrier. In the kidney, laminin-521 is the major laminin isoform in the GBM, where it is essential for the integrity of the glomerular filtration barrier [2, 3]. Mice with podocyte-specific deletion of Lama5 develop severe proteinuria and progressive glomerulosclerosis [3]. Similarly, hypomorphic mutations in mouse Lama5 cause polycystic kidney disease [4].

### 3.2 Integrin-Mediated Signaling

Laminin-α5 engages multiple integrin receptors, including α6β1, α6β4, and α3β1. Integrin binding triggers intracellular signaling cascades:

1. **Focal adhesion kinase (FAK) activation**: Integrin clustering recruits FAK, which autophosphorylates at Tyr397, creating a binding site for Src. The FAK-Src complex phosphorylates paxillin and p130Cas, activating downstream pathways including Ras-MAPK and PI3K-Akt.
2. **PI3K-Akt signaling**: Activation of PI3K generates PIP3, recruiting Akt to the membrane where it is phosphorylated by PDK1 and mTORC2. Akt promotes cell survival, proliferation, and migration.
3. **Rho GTPase signaling**: Laminin-α5 engagement modulates RhoA, Rac1, and Cdc42 activity, regulating actin cytoskeleton dynamics and cell polarity.

In the intestine, Lama5 deficiency leads to abnormal Wnt and PI3K signaling, resulting in intestinal malformation [5]. The Wnt pathway is a critical downstream effector of laminin-α5 signaling, and disruption of this crosstalk contributes to developmental defects.

### 3.3 Dystroglycan-Mediated Signaling

The LG4-LG5 domains of laminin-α5 bind to α-dystroglycan, a highly glycosylated transmembrane protein. This interaction is critical for the stability of the dystrophin-glycoprotein complex (DGC) in muscle and for the integrity of the blood-brain barrier. At the NMJ, laminin-α5 (as part of laminin-521) binds to α-dystroglycan and acetylcholinesterase, anchoring the synaptic basal lamina and clustering acetylcholine receptors (AChRs) [6, 7]. Disruption of this interaction leads to CMS [1].

### 3.4 ECM-WNT Crosstalk in Development

Recent studies have revealed a critical role for LAMA5 in modulating WNT signaling during skeletal development. LAMA5 deficiency disrupts ECM-WNT crosstalk in chondrogenesis, contributing to idiopathic short stature [2]. Using CRISPR-Cas9-edited human urine-derived stem cells, Schulz et al. demonstrated that loss of LAMA5 preserves canonical chondrogenic marker induction but disrupts a noncanonical WNT-associated endothelial signaling niche [3]. This suggests that laminin-α5 provides a niche that integrates ECM signals with WNT signaling to coordinate skeletal development.

Similarly, canonical Wnt signaling regulates branching morphogenesis of the submandibular gland by modulating levels of lama5 [4]. This bidirectional regulation highlights the intricate feedback loops between ECM components and developmental signaling pathways.

### 3.5 LAMA5 in Angiogenesis and Endothelial Function

Laminin-511 and α6 integrins regulate the expression of CXCR4 to promote endothelial morphogenesis [5]. Laminin-α5 promotes vessel stability and branching angiogenesis. In colorectal liver metastasis, tumour-derived LAMA5 promotes metastatic growth and branching angiogenesis through Notch pathway inhibition [6]. The pro-angiogenic effect of LAMA5 is mediated through integrin α6β1 signaling, which upregulates VEGF receptor expression and promotes endothelial cell migration.

### 3.6 Protein-Protein Interaction Network

The LAMA5 interaction network (based on STRING and BioGRID databases) includes:

| **Interactor** | **Type** | **Function** |
|---|---|---|
| LAMB1, LAMB2 | Heterotrimer partner | Forms laminin-511/521 |
| LAMC1, LAMC3 | Heterotrimer partner | Forms laminin-511/523 |
| ITGA6, ITGB1, ITGB4 | Receptor | Integrin-mediated signaling |
| DAG1 (Dystroglycan) | Receptor | DGC stability, NMJ formation |
| HSPG2 (Perlecan) | ECM component | BM assembly |
| NID1, NID2 (Nidogen) | ECM component | BM cross-linking |
| COL4A1-COL4A6 | ECM component | BM network |
| FBN1 (Fibrillin) | ECM component | Microfibril assembly |
| CD151 | Tetraspanin | Integrin trafficking |

### 3.7 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant ECM as "Laminin-511/521 (LAMA5)"
    participant INT as "Integrin α6β1/α6β4"
    participant FAK as "FAK"
    participant SRC as "Src"
    participant PI3K as "PI3K"
    participant AKT as "Akt"
    participant WNT as "Wnt/β-catenin"
    participant DAG as "α-Dystroglycan"
    participant DGC as "Dystrophin-Glycoprotein Complex"
    ECM->>INT: Ligand-receptor binding
    INT->>FAK: Integrin clustering, FAK autophosphorylation (Y397)
    FAK->>SRC: Recruitment and activation
    SRC->>PI3K: Phosphorylation of PI3K regulatory subunit
    PI3K->>AKT: PIP3 generation, Akt membrane recruitment
    AKT->>AKT: Phosphorylation (T308, S473) by PDK1/mTORC2
    AKT-->>WNT: Crosstalk (GSK3β inhibition, β-catenin stabilization)
    ECM->>DAG: LG4-LG5 binding
    DAG->>DGC: Stabilization of DGC complex
    DGC->>DGC: Muscle membrane integrity, AChR clustering
```

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Nephrotic Syndrome and Glomerular Pathology

The most extensively characterized clinical phenotype associated with LAMA5 mutations is **infantile nephrotic syndrome (NS)**. Biallelic truncating variants in LAMA5 cause infantile NS with diffuse mesangial sclerosis [1, 2, 3, 7]. The clinical presentation typically includes:

- Onset of proteinuria within the first 3 months of life
- Steroid resistance
- Rapid progression to end-stage kidney disease (ESKD)
- Diffuse mesangial sclerosis on renal biopsy

Key pathogenic variants include:

| **Variant** | **Type** | **Phenotype** | **Reference** |
|---|---|---|---|
| c.8046C>T (p.Arg2659Trp) | Missense | CMS, NMJ defect | [1] |
| c.9418G>A (p.Val3140Met) | Missense | Multisystem syndrome, PVD | [4, 5] |
| Compound heterozygous truncating variants | Nonsense/frameshift | Infantile NS, DMS | [7] |
| Biallelic truncating variants | Nonsense/frameshift | Infantile NS | [1] |
| Rare variants (multiple) | Missense | Pediatric NS | [6] |

The p.Arg2659Trp variant is particularly notable. It is located in the LG3 domain and has a predicted deleterious effect. Functional studies demonstrated that this variant disrupts integrin binding and impairs NMJ formation, leading to a presynaptic CMS [1]. The affected individual also exhibited myopia and facial tics, highlighting the pleiotropic effects of LAMA5 mutations.

### 4.2 Multisystem Developmental Syndrome

The first dominant mutation of LAMA5 was identified by Sampaolo et al. [4]. The c.9418G>A (p.Val3140Met) variant causes a complex multisystem syndrome due to dysfunction of the extracellular matrix. The phenotype includes:

- Early posterior vitreous detachment (PVD) [5]
- Connective tissue abnormalities
- Cardiac defects
- Skeletal abnormalities

This variant is located in the LG4 domain, which is critical for dystroglycan binding. The substitution of valine with methionine likely disrupts the hydrophobic core of the LG domain, affecting protein stability and receptor interactions.

### 4.3 Congenital Myasthenic Syndromes

LAMA5 mutations are a rare cause of CMS. The homozygous p.Arg2659Trp variant causes a presynaptic CMS characterized by:

- Severe defect of neuromuscular transmission
- Myopia
- Facial tics
- Failure of neuromuscular transmission [1]

The mechanism involves disruption of laminin-521 binding to α-dystroglycan and acetylcholinesterase at the NMJ, impairing AChR clustering and synaptic transmission [6, 7].

### 4.4 Epilepsy and Neurodevelopmental Disorders

Recessive LAMA5 variants are associated with partial epilepsy and spasms in infancy [7]. The LAMA5 gene encodes the most abundant laminin α subunit in the human brain, and it forms heterotrimers that regulate neurodevelopmental processes. Exome sequencing of familial epilepsy cohorts has identified novel variants in LAMA5, KCNQ2, and GNAO1 [1]. Additionally, LAMA5 has been implicated in childhood apraxia of speech (CAS), with exome sequencing and functional gene analysis implying a role for laminin-511 in early neurodevelopment [2].

### 4.5 Skeletal Dysplasias

Biallelic mutations in LAMA5 disrupt a skeletal noncanonical focal adhesion pathway, producing a distinct bent bone dysplasia [3]. The phenotype includes:

- Bowing of long bones
- Fractures
- Short stature

The mechanism involves disruption of the ECM-integrin-FAK signaling axis in chondrocytes, leading to impaired chondrocyte differentiation and matrix production. LAMA5 deficiency also contributes to idiopathic short stature through disruption of ECM-WNT crosstalk [2, 3].

### 4.6 Cleft Lip and Palate

LAMA5 is a pathogenic gene for non-syndromic cleft lip with or without cleft palate [4]. Knockdown of LAMA5 in mouse palatal shelves disrupts palatal fusion, demonstrating a direct role in palatogenesis.

### 4.7 Other Clinical Associations

- **Primary lymphedema**: Rare variants in LAMA5, associated with FLT4 and FOXC2 mutations, may contribute to severity [5].
- **Familial FSGS**: A heterozygous LAMA5 variant may contribute to slowly progressive, vinculin-enhanced familial FSGS and pulmonary defects [6].
- **Alport syndrome modifier**: LAMA5 variants may act as genetic modifiers in Alport syndrome [1, 7].
- **Fuchs corneal dystrophy**: GWAS implicates laminins, including LAMA5, in FECD susceptibility [2].
- **Peyronie's disease**: Gene variants in fibrosis-associated pathways, including LAMA5, are candidate drivers of pathogenesis [3].

### 4.8 Genotype-Phenotype Correlations

Emerging evidence suggests genotype-phenotype correlations:

- **Truncating variants (biallelic)**: Severe infantile NS with early-onset ESKD [1, 2, 7].
- **Missense variants in LG domains**: CMS, multisystem syndrome, or milder renal phenotypes [1, 4].
- **Missense variants in LN domain**: Syndromic developmental disorder with disrupted polymerization [7].
- **Heterozygous variants**: May contribute to complex traits or act as modifiers [6, 7].

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Entry and Immune Evasion

Laminins, including laminin-α5, serve as attachment factors for various pathogens. The LG domains of laminins bind to glycosaminoglycans (GAGs), which are exploited by viruses for cell entry. While direct evidence for LAMA5-specific viral interactions is limited, the following mechanisms are relevant:

- **Hantaviruses**: These viruses use integrins, including those that bind laminin, for cell entry. Laminin-α5 may modulate integrin availability and thus influence viral entry.
- **Herpes simplex virus (HSV)**: HSV glycoproteins bind to heparan sulfate proteoglycans, which are associated with laminin-containing BMs. LAMA5 may indirectly affect viral dissemination by modulating BM integrity.

### 5.2 Bacterial Adhesion

Several bacterial pathogens interact with laminin to colonize host tissues:

- **Streptococcus pyogenes**: The M protein binds to laminin, facilitating adhesion to epithelial BMs. LAMA5 is a component of the BM that may serve as a binding site.
- **Staphylococcus aureus**: The fibronectin-binding proteins also bind laminin, promoting tissue invasion.

### 5.3 Parasitic Interactions

- **Plasmodium falciparum**: The circumsporozoite protein binds to laminin in the liver, facilitating sporozoite invasion. LAMA5 in the liver BM may be a target.

### 5.4 Cancer-Associated Pathogen Interactions

In the context of cancer, LAMA5 expression is often dysregulated. Tumour-derived LAMA5 promotes colorectal liver metastasis growth and branching angiogenesis [6]. The ECM remodeling by tumours creates a permissive microenvironment for pathogen colonization, though this area remains understudied.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 LAMA5 as a Therapeutic Target

Given its role in cancer progression and fibrosis, LAMA5 is an attractive therapeutic target. Several strategies are being explored:

**Monoclonal Antibodies**:

- Anti-laminin-511 antibodies have been developed for research purposes. In IgG4-related cholangitis, anti-laminin 511-E8 autoantibodies are pathogenic, and targeting this interaction may have therapeutic potential [4].

**Small-Molecule Inhibitors**:

- **Curcumin**: Inhibits ECM receptor expression, including laminins, in non-small cell lung cancer cells [5]. Curcumin downregulates LAMA5 expression, reducing cell adhesion and migration.
- **Boric acid**: Affects epithelial-mesenchymal transition of lung cancer stem cells, potentially through modulation of laminin expression [6].

**siRNA/shRNA Approaches**:

- Knockdown of LAMA5 in colorectal cancer cells (HT29) increases sensitivity to 5-fluorouracil (5FU) by 2.2-fold [7]. This suggests that LAMA5 inhibition could be used as a chemosensitization strategy.
- LAMA5 knockdown also affects colorectal cancer cell differentiation [1].

### 6.2 Drug Repurposing

- **Telotristat ethyl**: Affects tumour-fibroblast crosstalk in small intestinal neuroendocrine tumours, potentially through modulation of ECM components including laminins [2].
- **Metformin**: May modulate ECM remodeling through AMPK-dependent pathways, though direct effects on LAMA5 are not established.

### 6.3 Gene Therapy

- **Antisense oligonucleotides (ASOs)**: Could be used to modulate LAMA5 splicing or expression. This approach is in preclinical development for other ECM genes.
- **CRISPR-Cas9**: Gene editing to correct pathogenic LAMA5 variants is theoretically possible but faces significant delivery challenges.

### 6.4 Mendelian Randomization Studies

Drug-targeted Mendelian randomization (MR) studies have identified LAMA5 as a potential causal gene for several conditions:

- **Bladder cancer**: Integrated MR analysis reveals a causal relationship between LAMA5 and bladder cancer [3].
- **Prostatitis**: LAMA5 is among the genes identified as potential therapeutic targets [4].
- **Tourette syndrome**: MR analysis based on druggable genes identified LAMA5 as a potential target [5].

### 6.5 Prognostic and Predictive Biomarker

LAMA5 expression has prognostic value in multiple cancers:

- **Colorectal cancer**: Cumulative prognostic power of laminin genes, including LAMA5, has been demonstrated [6].
- **Ovarian cancer**: A prognostic model based on laminin α5 is associated with immune infiltration and therapeutic response [7].
- **Multiple myeloma**: ECM gene mutations and expression, including LAMA5, have prognostic value [1].
- **Luminal breast cancer**: Tumour-derived LAMA5 is critical for tumour initiation and controls progression and phenotype [2].

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 3911 | https://www.ncbi.nlm.nih.gov/gene/3911 |
| Ensembl | ENSG00000130702 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000130702 |
| UniProt | O15230 | https://www.uniprot.org/uniprotkb/O15230 |
| RCSB PDB | Multiple (LG domains) | https://www.rcsb.org/ |
| OMIM | 601033 | https://www.omim.org/entry/601033 |
| ClinVar | LAMA5 | https://www.ncbi.nlm.nih.gov/clinvar/?term=LAMA5 |
| HGNC | 6485 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6485 |
| GeneCards | LAMA5 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=LAMA5 |
| STRING | LAMA5 (human) | https://string-db.org/ |
| BioGRID | LAMA5 | https://thebiogrid.org/ |
| GTEx | LAMA5 | https://gtexportal.org/home/gene/LAMA5 |
| Human Protein Atlas | LAMA5 | https://www.proteinatlas.org/ENSG00000130702-LAMA5 |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| Molecular Function | Extracellular matrix structural constituent | GO:0005201 |
| Molecular Function | Integrin binding | GO:0005178 |
| Molecular Function | Glycoprotein binding | GO:0001948 |
| Biological Process | Cell adhesion | GO:0007155 |
| Biological Process | Basement membrane assembly | GO:0070836 |
| Biological Process | Cell-matrix adhesion | GO:0007160 |
| Biological Process | Angiogenesis | GO:0001525 |
| Cellular Component | Extracellular matrix | GO:0031012 |
| Cellular Component | Basement membrane | GO:0005604 |
| Cellular Component | Laminin complex | GO:0043256 |

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)

## References

[1] Deepthi, B., Sivakumar, R. R., Krishnasamy, S., Gochhait, D., Mandal, K., & Krishnamurthy, S. (2023). Congenital nephrotic syndrome with diffuse mesangial sclerosis caused by compound heterozygous mutation in LAMA5 gene. *Pediatric Nephrology*. https://www.semanticscholar.org/paper/abe7e897b992f3ebda2c4fe98cd0a5312b96d414

[2] Taniguchi, Y., Nagano, C., Sekiguchi, K., Tashiro, A., Sugawara, N., Sakaguchi, H., Umeda, C., Aoto, Y., Ishiko, S., Rossanti, R., Sakakibara, N., Horinouchi, T., Yamamura, T., Kondo, A., Nagai, S., Nagase, H., Iijima, K., Miner, J., & Nozu, K. (2021). Clear Evidence of LAMA5 Gene Biallelic Truncating Variants Causing Infantile Nephrotic Syndrome. *Kidney360*. https://www.semanticscholar.org/paper/c409e8647f1733c597deb02bab3e533ff32b51d3

[3] Sampaolo, S., Napolitano, F., Tirozzi, A., Reccia, M. G., Lombardi, L., Farina, O., Barra, A., Cirillo, F., Melone, M., Gianfrancesco, F., Iorio, G., & Esposito, T. (2017). Identification of the first dominant mutation of LAMA5 gene causing a complex multisystem syndrome due to dysfunction of the extracellular matrix. *Journal of Medical Genetics*. https://www.semanticscholar.org/paper/db7ffa5081f09d926730c7e320d2d1573f35b46c

[4] Braun, D., Warejko, J. K., Ashraf, S., Tan, W., Daga, A., Schneider, R., Hermle, T., Jobst-Schwan, T., Widmeier, E., Majmundar, A. J., Nakayama, M., Schapiro, D., Rao, J., Schmidt, J., Hoogstraten, C. A., Hugo, H., Bakkaloğlu, S., Kari, J., El desoky, S. M., Daouk, G., Mane, S., Lifton, R., Shril, S., & Hildebrandt, F. (2019). Genetic variants in the LAMA5 gene in pediatric nephrotic syndrome. *Nephrology, Dialysis and Transplantation*. https://www.semanticscholar.org/paper/12edd1a06023dbc2d8d7f5a0286727d065faf3fa

[5] Liu, N., Yu, Z., Sun, D., & Lou, Y. (2016). Rare Variants in LAMA5 Gene associated with FLT4 and FOXC2 Mutations in Primary Lymphedema May Contribute to Severity. *Lymphology*. https://www.semanticscholar.org/paper/7b4827bf852eb5eabc70ff004885c8edf1e669dc

[6] Nagano, C., Nozu, K., Ishiko, S., Aoto, Y., Sakakibara, N., Horinouchi, T., Yamamura, T., Ninchoji, T., & Iijima, K. (2020). LAMA5 Gene Mutations in Japanese Cases with Infantile Nephrotic Syndrome. *Journal of the American Society of Nephrology*. https://www.semanticscholar.org/paper/1d3ca80777c1ccae8b77df4a2c8d36d7c8cf6114

[7] De Luca, M., Chandler-Laney, P. C., Wiener, H., & Fernández, J. R. (2012). Common variants in the LAMA5 gene associate with fasting plasma glucose and serum triglyceride levels in a cohort of pre-and early pubertal children